José Manuel Fernández-Real, Jordi Mayneris Perxachs, María Arnorriaga, Rafael Maldonado, Aurelius Burokas. Gut microbiota composition and uses thereof. 20382592.2-1112

Rafael Maldonado, David Andreu, Maria Gallo, Leonardo Pardo, Vicent Casadó, Estefania Moreno, Miguel Castanho, Vera Neves, Marco Cavaco. Peptide compounds for reducing side effects of CB1 receptor agonists. PCT/EP2020/077642

Begoña Fernández Pastor, Alba Vidal Torres, Mireia Carcolé Estrada, Rafael Maldonado López, José Miguel Vela Hernández, Manuel Merlos Roca, Daniel Zamanillo Castanedo. Use of (R)-9-(2-5-difluorophenethyl)-4-ethyl-2-methyl-1-oxa-4,9-diazaspiro [5.5]undecan-3-one for the treatment of nociceptive pain, neuropathic pain, osteoarthritis pain and cancer pain, while having reduced side effects compared to opioids. PCT/EP2020/071096

Pier-Vincenzo Piazza, Sandy Fabre, Stéphanie Monlezun, Mathilde Metna, Monique Vallée, Jean-Michel Revest, Daniela Cota, Giovanni Marsicano, Aline Marsighetto, Andrés Ozaita, Rafael Maldonado. 3beta-(benzyloxy)-17 alpha-methyl-pregn-5-en-20-one for use in the treatment of cognitive disorders. PCT/EP2019/085927

Geoffrey Guy, Stephen Wright, James Brodie, Marie Wooley-Roberts, Rafael Maldonado, Daniela Parolaro, Livio Luongo. Use of cannabidiolic acid in the treatment of autism spectrum disorder and associated disorders. PCT/GB2017/051010

Geoffrey Guy, Stephen Wright, James Brodie, Marie Wooley-Roberts, Rafael Maldonado, Daniela Parolaro, Livio Luongo, Joanne Neill. Use of cannabidivarin in the treatment of autism spectrum disorder, associated disorders and schizophrenia. PCT/GB2017/051007

Ozaita A, Busquets-Garcia A, Maldonado R. Antagonists of the cannabinoid receptor CB1 for use in the treatment of diseases associated with neuronal dendritic abnormalities. PCT/EP2013/055728. 2013.